The renal protective effects of cilostazol on suppressing pathogenic thrombospondin-1 and transforming growth factor-β expression in streptozotocin-induced diabetic rats

Journal of International Medical Research

Volumn 37, Issue 1, 2009, Pages 145-153

  Wang, X ^a   Yan, L ^a   Chen, W ^a   Xu, L ^a   Zhang, Xiaoming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cilostazol; Diabetes mellitus; Diabetic nephropathy; Phosphodiesterase III inhibitor; Rat model of diabetes mellitus; Streptozotocin induced diabetes mellitus; Thrombospondin 1; Transforming growth factor

Indexed keywords

CILOSTAZOL; GLUCOSE; MESSENGER RNA; PHOSPHODIESTERASE III INHIBITOR; STREPTOZOCIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY STRUCTURE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STREPTOZOCIN; TETRAZOLES; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 64149106032     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700117     Document Type: Article

References (26)

1. Pinhas-Hamiel O, Zeitler P: Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007; 1 369: 1823-1831.
2. Mundet X, Pou A, Piquer N, et al: Prevalence and incidence of chronic complication and mortality in a cohort of type 2 diabetic patients in Spain. Prim Care Diabetes 2008; 2: 135-140.
3. Zhang XD, Chen YR, Ge L et al: Features of stoke in Chinese diabetes patients: a hospital based Addy. J Int Med Res 2007; 35: S40-546.
4. Ringborg A. Lindgren, Martinell M, et al: Prevalence and incidence of Type 2 diabetes and its complications 1996; 2003 - estimates from a Swedish population-based study. Diabet Med 2008; 25: 117-1186.
5. Hong D, Zheng T, Jia-Qing S, et al: Nodular glomerular lesion: a later stage of diabetic nephropathy? Diabetes Res Clin Pract 2007; 78: 189-195.
6. Daniel C, Schaub K, Amann K, et al: Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 2007; 56: 2982-2989.
7. Falconer TM, Eikelboom JW, Hankey GJ, et al: Management of peripheral arterial disease in the elderly: focus on cilostazol. Clin Interv Aging 2008; 3: 17-23.
8. Gao L, Wang F, Wang B, et al: Cilostazol protects diabetic rats from vascular inflammation via nuclear factor-κB-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther 2006; 318: 53-58.
9. Koike N, Takamura T, Kaneko S: Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-α stimulation, and effects of a phosphodiesterase inhibitor. Life Sci 2007; 80: 1721-1728.
10. Tohma T, Shimabukuro M, Oshiro Y, et al: Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. Metabolism 2004; 53: 140S-1410.
11. Rosa MP, Baroni GV, Portal VL.: Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol. Arq Bras Endocrinol Metabol 2007; 51: 1528-1S32 [in Portuquese].
12. Zhang XG, Yan H, Shen YL, et al: Decreased thrombospondin-1 (TSP-1) expression in the hippocampus of streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes 2008; 116: 309-314.
13. Ma J, Zheng M, Shen Y, et al: Effects of cilostazol on thrombospondin-1 (TSP-1) expression changes in the myocardium of diabetic rats. J Int Med Res 2008, 36: 800-809.
14. Weng Y, Shen F, Li J, et al: Expression changes of mitogen-activated protein kinase phosphatase-1 (MKP-1) in myocardium of streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes 2007; 115: 455-460.
15. Tesch GH, Allen TJ: Rodent models of streptozotocin-induced diabetic nephropathy Nephrology (Cariton) 2007; 12: 261-266.
16. Li JJ, Kwak SJ, Jung DS, et al: Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007; 166: S36-S42.
17. Thomas MC, Burns WC, Cooper ME: Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 200S; 12: 177-186.
18. Adams JC, Lawler J: The thrombospondins. Int J Biochem Cell Biol 2004; 36: 961-968.
19. Tada H, Kuboki K, Nomura K, et al: High qlucose levels enhance TGF-β-thrombospondin-1 pathway in cultured human mesangial cells via mechanisms dependent on glucose-incluced PKC activation. J Diabetes Complications 2001; 15: 193-197.
20. Hohenstein B, Daniel C, Hausknecht B, et al: Correlation of enhanced thrombospondin-1 expression, TGF-β signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 3880-3887.
21. Pantsulaia T: Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Med News 2006; 131: 13-18.
22. Hohenstein B, Daniel C, Hausknecht B, et al: Correlation of enhanced tbrombospondin-1 expression, TGF-β signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 3880-3987.
23. Omi H, Okayama N, Shimizu M, et al: Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvasc Res 2004; 68: 119-12S.
24. Sudo T, Ito H, Kimura Y: Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets 2003; 14: 381-390.
25. S Ito C, Kusano E, Akimoto T, et al: Cilostazol enhances IL-1β-induced NO production and apoptosis in rat vascular smooth muscle via PKA-dependent pathway. Cell Signal 2002; 14: 625-632.
26. Matsumoto T, Wakabayashi K, Kobayashi T, et at: Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am J Physiol Heart Circ Physiol 2004; 297: H1064-H1071.